A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

ClinicalTrials.gov ID: NCT05123703

Public ClinicalTrials.gov record NCT05123703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.

Study identification

NCT ID: NCT05123703
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 188 participants

Conditions and interventions

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 10 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 18, 2022
Primary completion: Jun 8, 2025
Completion: Sep 16, 2029
Last update posted: Jul 14, 2026

2022 – 2029

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
UC San Diego	La Jolla	California	92037-1337	—
Children's Hospital Colorado	Aurora	Colorado	80045	—
Children's National Hospital	Washington D.C.	District of Columbia	20010	—
Johns Hopkins Medicine	Baltimore	Maryland	21287	—
Boston Children's Hospital Central Pharmacy	Boston	Massachusetts	02115-5724	—
Washington University	St Louis	Missouri	63101	—
Cleveland Clinic, Mellen Center for Multiple Sclerosis	Cleveland	Ohio	44195-0001	—
The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company	Columbus	Ohio	43235	—
The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104-4319	—
Baylor College of Medicine/Texas Children's Hospital	Houston	Texas	77030-2608	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05123703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 14, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05123703 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →